BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Abbott unveils Next-Generation XIENCE Sierra stent in India

02 May 2024 | News

XIENCE Sierra demonstrates flexibility and precision, enabling physicians to access and unblock difficult-to-treat blockages



Abbott, the global healthcare company, has announced the launch of XIENCE Sierra Everolimus (drug) Eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE family, now available to people suffering from blocked coronary arteries. For interventional cardiologists, it brings unparalleled safety to the most complex cases.

Abbott has developed several tools and devices that have improved the angioplasty procedure over the years. Percutaneous coronary intervention (PCI), also called coronary angioplasty, is a nonsurgical, minimally invasive procedure that improves blood flow to the heart. Physicians use PCI to open blood vessels to the heart that are narrowed or blocked by plaque. Often, a small mesh tube called a stent is placed to keep the artery open.

XIENCE is one of the most-used drug-eluting stents in the world. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases. XIENCE Sierra has the same highly specialised coating that lowers the likelihood of the artery becoming re-blocked, found in other XIENCE stents. The stents collectively have an unparalleled safety record from more than 120+ clinical trials involving 120,000 patients. As per published data, the stent has proved efficacy in difficult to treat, narrowed lesions and patients with complex conditions.